☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Bavarian Nordic
Bavarian Nordic Reports the US FDA’s BLA Acceptance of CHIKV VLP Vaccine to Prevent Chikungunya
August 14, 2024
Bavarian Nordic’s CHIKV VLP Receives EMA’s Accelerated Assessment for Chikungunya
February 24, 2024
Bavarian Nordic Reports P-III Clinical Trial Results of CHIKV VLP (PXVX0317) for Chikungunya Virus Vaccine in Adults and Adolescen...
August 7, 2023
Bavarian Nordic to Acquire Emergent BioSolutions’ Vivotif, Vaxchora and an Under Developed Chikungunya Vaccine
February 15, 2023
Bavarian Nordic Reports the First Patient Dosing in P-III (VANIR) Trial for the Treatment of Respiratory Syncytial Virus
April 20, 2022
Bavarian Nordic’s MVA-BN RSV Receives the US FDA’s Breakthrough Therapy Designation for Prevention of Respiratory Syncytial Virus
February 14, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.